Research Topics
| Michele DonatoSummaryAffiliation: The University of Texas Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood unitsMarcos de Lima
Department of Blood and Marrow Transplantation, Pathology, and Leukaemia, M D Anderson Cancer Center, Houston, TX 77030, USA
Br J Haematol 119:773-6. 2002..Triple chimaerism was present from relapse until death due to leukaemia. This approach may potentially improve UCB transplantation outcome for adults lacking a histocompatible donor...- Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndromeM De Lima
Department of Stem Cell Transplantation and Cell Therapy, U T M D Anderson Cancer Center, Houston, TX 77030 4009, USA
Leukemia 22:258-64. 2008..Median follow-up was 37 months. Median event-free and overall survival was 6 and 11 months. GO 2 mg m(-2) can be safely added to fludarabine/melphalan, and this regimen merits further evaluation... 
Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trialM De Lima
Department of Stem Cell Transplantation and Cell Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Bone Marrow Transplant 41:771-8. 2008..Median time to neutrophil and platelet engraftment was 30 (range, 16-46) and 48 (range, 35-105) days. There were no cases of grades 3-4 acute graft-versus-host disease (GVHD) and 100-day survival was 90%. This strategy is feasible...- Ex-vivo purging of hematopoietic progenitor cellsMarcos de Lima
Department of Blood and Marrow Transplantation, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030, USA
Curr Hematol Rep 3:257-64. 2004.... - Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndromeMarcos de Lima
Department of Blood and Marrow Transplantation, M D Anderson Cancer Center, Houston, TX 77033, USA
Semin Hematol 43:107-17. 2006..Here we review current results of allogeneic blood and marrow transplantation for AML and MDS in the elderly... - Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding studyMarcos de Lima
Department of Stem Cell Transplantation and Cell Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 116:5420-31. 2010..The authors hypothesized that low-dose azacitidine administered after transplant would reduce recurrence rates, and conducted a study to determine a safe dose/schedule combination... - Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantationMarcos de Lima
Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Blood 104:865-72. 2004..Survival was improved for patients in CR at transplantation. In conclusion, FM provided better disease control though at a cost of increased TRM and morbidity... - Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDSMarcos de Lima
Department of Blood and Marrow Transplantation, MD Anderson Cancer Center, Houston, TX 77030, USA
Blood 104:857-64. 2004..The results suggest that intravenous busulfan-fludarabine is an efficacious, reduced-toxicity, myeloablative-conditioning regimen for patients with AML or MDS undergoing HSCT... - Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemiasMarcos de Lima
Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
Cancer 97:1242-7. 2003..Decitabine is a hypomethylating agent that has activity in patients with leukemia. The authors combined decitabine with busulfan and cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation... - Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndromeMadeleine Duvic
Department of Dermatology, MD Anderson Cancer Center, Houston, Texas 77030, USA
J Clin Oncol 28:2365-72. 2010..We studied the safety and efficacy of total skin electron beam with allogeneic hematopoietic stem-cell transplantation (HSCT) in patients with cutaneous T-cell lymphoma (CTCL)... - Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalanBetul Oran
M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Biol Blood Marrow Transplant 13:454-62. 2007..Use of unrelated donors increased the risk of NRM only among patients with active disease. FM and HSCT elicited long-term disease control in a significant fraction of this high-risk cohort... - Tumor necrosis factor-alpha blockade for the treatment of acute GVHDDaniel Couriel
Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Blood 104:649-54. 2004..Survival after steroid-resistant acute GVHD continues to be problematic. The possibility of excessive fungal and other infections must be explored further... - Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatmentBetul Oran
Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Biol Blood Marrow Transplant 13:469-77. 2007..Control of TAM generally requires response of associated infections and GVHD. TMA response may occur despite continuation of tacrolimus treatment... - Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work?Daniel Couriel
Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Biol Blood Marrow Transplant 12:37-40. 2006..All of these results indicate activity of extracorporeal photopheresis in acute and chronic GVHD, which warrants further evaluation of this therapy in well-designed, prospective, controlled studies... - Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHDDaniel R Couriel
Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 423, Houston, TX 77030, USA
Blood 107:3074-80. 2006..Objective responses were observed in a substantial number of patients with both skin and visceral chronic GVHD failing corticosteroids and other immunosuppression... - Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemiaMuzaffar H Qazilbash
Department of Blood and Marrow Transplantation, UT MD Anderson Cancer Center, Houston, 77030, USA
Am J Hematol 80:43-5. 2005..The patient developed autoimmune hemolytic anemia that failed to respond to steroids, intravenous immunoglobulins, and plasma exchange. She was then treated with rituximab that resulted in fatal acute liver toxicity... - Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myelomaAthanasios Anagnostopoulos
Department of Blood and Marrow Transplantation, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 100:2607-12. 2004..HDM should continue to be considered the standard preparative regimen for patients with myeloma... - Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantationMaricer P Escalon
Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 22:2419-23. 2004..We investigated the safety and efficacy of nonmyeloablative stem-cell transplantation in these patients... - A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosisShreyaskumar R Patel
The Sarcoma Center, The University of Texas M D Anderson Cancer Center, PO Box 450, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Cancer 101:156-63. 2004..The authors evaluated the efficacy and toxicity of cisplatin, ifosfamide, and doxorubicin with peripheral blood stem cell (PBSC) support in adult patients with osteosarcomas and variants with a poor prognosis... 
Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized studySimrit Parmar
Department of Stem Cell Transplantation and Cell Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX 77030, USA
J Clin Oncol 29:294-302. 2011....
Research Grants
- A Novel Autotransplant Protocol for CMLMarcos de Lima; Fiscal Year: 2005..abstract_text> ..